BackSAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt) Overview

SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt) Receivables

Latest receivables for BCYPU: $1.6M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$1.56M
↑ 7171.40% YoYΔ $1.53M vs prior year quarter

Peer average

Loading

SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt) Receivables History

Loading

SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt) vs. peers: Receivables Comparison

Loading

SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt) Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt) (BCYPU) FAQ

As of the most recent data (March 2026), BCYPU shows a receivables of $1.6M. That compares with $21K in the prior-year period — up 7171.4% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BCYPU's receivables is now $1.6M (was $21K) — a 7171.4% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt) is outperforming or lagging.

Tracking BCYPU's receivables over time shows whether SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt) is scaling, shrinking, or reshaping that part of the business. The current reading is $1.6M That compares with $21K in the prior-year period — up 7171.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $1.6M) with ownership activity and broader fundamentals.